Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash to Debt No Debt
ARQL's Cash to Debt is ranked higher than
96% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. ARQL: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ARQL' s Cash to Debt Range Over the Past 10 Years
Min: 2.7  Med: 26.59 Max: No Debt
Current: No Debt
Equity to Asset 0.73
ARQL's Equity to Asset is ranked higher than
56% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ARQL: 0.73 )
Ranked among companies with meaningful Equity to Asset only.
ARQL' s Equity to Asset Range Over the Past 10 Years
Min: -0.16  Med: 0.66 Max: 0.9
Current: 0.73
-0.16
0.9
F-Score: 4
Z-Score: -11.18
M-Score: -1.67
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -125.92
ARQL's Operating margin (%) is ranked lower than
56% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. ARQL: -125.92 )
Ranked among companies with meaningful Operating margin (%) only.
ARQL' s Operating margin (%) Range Over the Past 10 Years
Min: -790.25  Med: -153.58 Max: -23.41
Current: -125.92
-790.25
-23.41
Net-margin (%) -122.56
ARQL's Net-margin (%) is ranked lower than
58% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. ARQL: -122.56 )
Ranked among companies with meaningful Net-margin (%) only.
ARQL' s Net-margin (%) Range Over the Past 10 Years
Min: -582.35  Med: -149.00 Max: -22.75
Current: -122.56
-582.35
-22.75
ROE (%) -40.21
ARQL's ROE (%) is ranked lower than
56% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. ARQL: -40.21 )
Ranked among companies with meaningful ROE (%) only.
ARQL' s ROE (%) Range Over the Past 10 Years
Min: -141.91  Med: -46.24 Max: -19.63
Current: -40.21
-141.91
-19.63
ROA (%) -27.29
ARQL's ROA (%) is ranked lower than
51% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. ARQL: -27.29 )
Ranked among companies with meaningful ROA (%) only.
ARQL' s ROA (%) Range Over the Past 10 Years
Min: -43.21  Med: -23.58 Max: -8.65
Current: -27.29
-43.21
-8.65
ROC (Joel Greenblatt) (%) -6115.82
ARQL's ROC (Joel Greenblatt) (%) is ranked lower than
82% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. ARQL: -6115.82 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ARQL' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -7093.73  Med: -966.28 Max: -332.62
Current: -6115.82
-7093.73
-332.62
Revenue Growth (3Y)(%) -33.50
ARQL's Revenue Growth (3Y)(%) is ranked lower than
80% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. ARQL: -33.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ARQL' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -61  Med: 9.60 Max: 45.3
Current: -33.5
-61
45.3
EBITDA Growth (3Y)(%) 10.80
ARQL's EBITDA Growth (3Y)(%) is ranked higher than
66% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. ARQL: 10.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ARQL' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -46.3  Med: 14.20 Max: 118.5
Current: 10.8
-46.3
118.5
EPS Growth (3Y)(%) 6.40
ARQL's EPS Growth (3Y)(%) is ranked higher than
63% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. ARQL: 6.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ARQL' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -48.4  Med: -4.30 Max: 119.3
Current: 6.4
-48.4
119.3
» ARQL's 10-Y Financials

Financials (Next Earnings Date: 2016-05-03)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

ARQL Guru Trades in Q1 2015

First Eagle Investment 5,719,968 sh (+28.69%)
Jim Simons 1,873,783 sh (+22.25%)
Chuck Royce Sold Out
» More
Q2 2015

ARQL Guru Trades in Q2 2015

First Eagle Investment 8,719,968 sh (+52.45%)
Jim Simons 2,103,655 sh (+12.27%)
» More
Q3 2015

ARQL Guru Trades in Q3 2015

First Eagle Investment 8,719,968 sh (unchged)
Jim Simons 1,936,544 sh (-7.94%)
» More
Q4 2015

ARQL Guru Trades in Q4 2015

Jim Simons 2,270,089 sh (+17.22%)
First Eagle Investment 8,719,968 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ARQL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Arqule Inc

Jean-Marie Eveillard Increases Stakes in Cancer Therapeutics Company Arqule Inc
Jean-Marie Eveillard recently increased his stakes in biotech company Arqule Inc (NASDAQ:ARQL), according to GuruFocus Real Time Picks. Read more...

Ratios

vs
industry
vs
history
P/B 3.53
ARQL's P/B is ranked lower than
52% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. ARQL: 3.53 )
Ranked among companies with meaningful P/B only.
ARQL' s P/B Range Over the Past 10 Years
Min: 1.46  Med: 2.94 Max: 113.05
Current: 3.53
1.46
113.05
P/S 9.10
ARQL's P/S is ranked higher than
56% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. ARQL: 9.10 )
Ranked among companies with meaningful P/S only.
ARQL' s P/S Range Over the Past 10 Years
Min: 2.78  Med: 9.32 Max: 99.04
Current: 9.1
2.78
99.04
Current Ratio 3.65
ARQL's Current Ratio is ranked lower than
58% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. ARQL: 3.65 )
Ranked among companies with meaningful Current Ratio only.
ARQL' s Current Ratio Range Over the Past 10 Years
Min: 1.48  Med: 3.41 Max: 7.45
Current: 3.65
1.48
7.45
Quick Ratio 3.65
ARQL's Quick Ratio is ranked lower than
55% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. ARQL: 3.65 )
Ranked among companies with meaningful Quick Ratio only.
ARQL' s Quick Ratio Range Over the Past 10 Years
Min: 1.48  Med: 3.41 Max: 7.36
Current: 3.65
1.48
7.36

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.70
ARQL's Price/Net Cash is ranked higher than
65% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: 5.42 vs. ARQL: 3.70 )
Ranked among companies with meaningful Price/Net Cash only.
ARQL' s Price/Net Cash Range Over the Past 10 Years
Min: 1.91  Med: 4.48 Max: 49.87
Current: 3.7
1.91
49.87
Price/Net Current Asset Value 3.54
ARQL's Price/Net Current Asset Value is ranked higher than
66% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 5.24 vs. ARQL: 3.54 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ARQL' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.73  Med: 4.13 Max: 44.57
Current: 3.54
1.73
44.57
Price/Tangible Book 3.54
ARQL's Price/Tangible Book is ranked higher than
57% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. ARQL: 3.54 )
Ranked among companies with meaningful Price/Tangible Book only.
ARQL' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.7  Med: 2.87 Max: 14.3
Current: 3.54
0.7
14.3
Price/Median PS Value 0.98
ARQL's Price/Median PS Value is ranked lower than
52% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. ARQL: 0.98 )
Ranked among companies with meaningful Price/Median PS Value only.
ARQL' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.11  Med: 0.74 Max: 3.62
Current: 0.98
0.11
3.62
Earnings Yield (Greenblatt) (%) -22.20
ARQL's Earnings Yield (Greenblatt) (%) is ranked lower than
72% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. ARQL: -22.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ARQL' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -230.1  Med: 0.00 Max: 0
Current: -22.2
-230.1
0

More Statistics

Revenue(Mil) $11
EPS $ -0.22
Beta1.85
Short Percentage of Float2.49%
52-Week Range $1.37 - 2.65
Shares Outstanding(Mil)62.93

Analyst Estimate

Dec17 Dec18
Revenue(Mil) 14 29
EPS($) -0.27 -0.40
EPS without NRI($) -0.27 -0.40

Business Description

Industry: Biotechnology » Biotechnology
Compare:TPE:1734, ASX:VLA, NAS:AFMD, NAS:DPRX, XPAR:CEREN, TSX:HBP » details
Traded in other countries:AQL.Germany,
Arqule Inc was organized as a Delaware corporation in 1993 in Delaware. The Company is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. It employ technologies such as its ArQule Kinase Inhibitor Platform ("AKIPTM") to design and develop drugs that have the potential to fulfill this mission. Its product candidates and programs span a continuum of research and development ranging from drug discovery to advanced clinical testing. Its product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase. C-Met is a promising target for cancer therapy, based on its multiple roles in cancerous cell proliferation, tumor spread, new blood vessel formation and resistance to certain drug therapies. The Company and its partners, Daiichi Sankyo Co., Ltd. ('Daiichi Sankyo') and Kyowa Hakko Kirin Co., Ltd. ('Kyowa Hakko Kirin'), are implementing a clinical development program designed to realize the broad potential of tivantinib as a well-tolerated single agent and in combination with other anti-cancer therapies in a number of disease indications The Company has licensed commercial rights to tivantinib for human cancer indications to Daiichi Sankyo in the U.S., Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin. Its proprietary pipeline is directed toward molecular targets and biological processes with demonstrated roles in the development of human cancers. The advanced candidates in this pipeline are ARQ 087, an inhibitor of fibroblast growth factor receptor, ARQ 621, an inhibitor of the Eg5 kinesin motor protein, and ARQ 736, an inhibitor of the RAF kinases, all of which are in Phase 1 clinical testing. Its drug discovery efforts are engaged mainly on AKIP, which it is using to generate compounds designed to inhibit kinases without competing with adenosine triphosphate ('ATP') for binding to the target kinase, as well as other types of kinase inhibitors. ATP is a chemical found in all living cells and is the energy source involved in a variety of physiological processes. The Company faces competition from pharmaceutical companies, biotechnology companies and academic and research organizations. The Company's product candidates, as well as the activities associated with their research, development and commercialization, are subject to extensive regulation by the FDA in the United States and by comparable authorities in other countries.
» More Articles for ARQL

Headlines

Articles On GuruFocus.com
Jean-Marie Eveillard Increases Stakes in Cancer Therapeutics Company Arqule Inc May 05 2015 
Jean-Marie Eveillard Adds to Stake in Arqule Inc. May 03 2015 
ArQule Inc. Reports Operating Results (10-Q) Nov 09 2010 
ArQule Inc. Reports Operating Results (10-Q) Aug 04 2010 
ArQule Inc. Reports Operating Results (10-Q) May 06 2010 
ArQule Inc. (ARQL) CEO Paolo Pucci buys 5,000 Shares Nov 13 2009 
ArQule Inc. Reports Operating Results (10-Q) Aug 07 2009 
ArQule Inc. (ARQL) CEO Paolo Pucci buys 2,500 Shares May 15 2009 
ArQule Inc. Reports Operating Results (10-Q) May 08 2009 

More From Other Websites
ArQule To Report First Quarter 2016 Financial Results On May 4, 2016 Apr 20 2016
ArQule to Present at the 15th Annual Needham Healthcare Conference on April 12, 2016 Apr 18 2016
ARQULE INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Apr 14 2016
ArQule to Present at the 15th Annual Needham Healthcare Conference on April 12, 2016 Apr 05 2016
ETF’s with exposure to ArQule, Inc. : March 28, 2016 Mar 28 2016
ARQULE INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 22 2016
Daiichi Sankyo and ArQule Announce Continuation of METIV-HCC Phase 3 Study of Tivantinib in... Mar 22 2016
Pfizer Inc (PFE) Reports 4.4% Position in Arqule Inc (ARQL) Mar 18 2016
ETF’s with exposure to ArQule, Inc. : March 14, 2016 Mar 14 2016
ArQule, Inc. :ARQL-US: Earnings Analysis: Q4, 2015 By the Numbers Mar 14 2016
ARQULE INC Financials Mar 08 2016
ARQULE INC Files SEC form 8-K/A, Other Events Mar 04 2016
Edited Transcript of ARQL earnings conference call or presentation 29-Feb-16 2:00pm GMT Feb 29 2016
ArQule Inc Earnings Call scheduled for 9:00 am ET today Feb 29 2016
ARQULE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and... Feb 29 2016
ArQule reports 4Q loss Feb 29 2016
ArQule reports 4Q loss Feb 29 2016
Q4 2015 ArQule Inc Earnings Release - Before Market Open Feb 29 2016
ArQule Reports Fourth Quarter and Full Year 2015 Financial Results Feb 29 2016
ArQule Announces $15.3 Million Registered Direct Offering of Common Stock Feb 29 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK